Drugs / aQIV
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT05044195 | Sep 2021 → Jan 2022 | influenza | Seqirus | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | aQIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05044195 ↗ |
| Modality | Vaccine | “aQIV (an MF59-adjuvanted quadrivalent influenza vaccine)” NCT05044195 ↗ |
| Route | Intramuscular | “intramuscular dose” NCT05044195 ↗ |